Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure

Gut

Volumn 44, Issue 6, 1999, Pages 800-807

  Wirtz, S ^a   Galle, P R ^a   Neurath, M F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Adenovirus; Coliris; Colon; Gene transfer

Indexed keywords

BETA GALACTOSIDASE; TRINITROBENZENESULFONIC ACID; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; CHEMOLUMINESCENCE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE TARGETING; HUMAN CYTOMEGALOVIRUS; LAMINA PROPRIA; LIVER; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SPLEEN; T LYMPHOCYTE; VIRUS RECOMBINANT;

EID: 0033055144     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.6.800     Document Type: Article

References (48)

1. Strober W, Neurath MF. Immunological diseases of the gastrointestinal tract. In: Rich RR, ed. Clinical immunology. St Louis: Mosby, 1995:1401-28.
2. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
3. Strober W, Kelsall BL, Fuss I, et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 1997;18:61-4.
4. Powrie, F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995;3:171-4.
5. Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998;187:389-402.
6. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
7. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
8. Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors. Curr Opin Biotechnol 1994;5:617-25.
9. Wilson JM. Adenovirus as gene-delivery vehicles. N Engl J Med 1996;334:1185-7.
10. Cheng DY, Kolls JK, Lei D, et al. In vivo and in vitro gene transfer and expression in rat intestinal epithelial cells by E1-deleted adenoviral vector. Hum Gene Ther 1997;8:755-64.
11. Noel RA, Shukla P, Henning SJ. Optimization of gene transfer into intestinal epithelial cells using a retroviral vector. J Pediatr Gastroenterol Nutr 1994;19:43-9.
12. Lozier JN, Yankaskas JR, Ramsey WJ, et al. Gut epithelial cells as targets for gene therapy of hemophilia. Hum Gene Ther 1997;18:1481-90.
13. Kass-Eisler A, Falck-Pederson E, Alvira M, et al. Quantitative determination of adenovirus-mediated gene delivery to cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA 1993;90:11498-502.
14. Huard J, Lochmuller H, Acsadi G, et al. Differential short-term transduction efficiency of adult versus newborn mouse tissues by adenoviral recombinants. Exp Mol Pathol 1995;62:131-43.
15. Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant alpha-I-antitrypsin gene to the lung epithelium in vivo. Science 1991;270:431-4.
16. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-4.
17. Le Gal La Salle G, Robert JJ, Bernard S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993;259:988-90.
18. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997;8:985-1001.
19. Stewart AK, Lassam NJ, Graham FL, et al. Phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. Hum Gene Ther 1997;8:1403-14.
20. Li Q, Kay MA, Finegold M, et al. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993;4:403-9.
21. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996;70:8934-43.
22. Bett AJ, Haddara W, Prevec L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994;91:8802-6.
23. Graham FL, Smiley J, Russel WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-72.
24. Graham FL, Prevec, L. Manipulation of adenovirus vectors. Methods Mol Biol 1991;7:109-28.
25. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
26. Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996;183:2605-16.
27. Brown GR, Thiele DL, Silva M, et al. Adenoviral vectors given intravenously to immunocompromised mice yield stable transduction of the colonic epithelium. Gastroenterology 1997;112:1586-94.
28. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928-37.
29. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins avβ3 and avβ5 promote adenovirus internalisation but not virus attachment. Cell 1993;73:309-19.
30. Huang S, Endo RI, Nemerow G. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995;694:2257-63.
31. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11.
32. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995;155:2564-70.
33. Van Dullemen HM, van Deventer SJ, Hommes Bijl HA, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody cA2. Gastroenterology 1995;109:129-35.
34. van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease. Gastroenterology 1997;113:383-9.
35. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
36. Neurath MF, Pettersson S, Meyer-zum BK, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996;2: 998-1004.
37. Jobin C, Panja A, Hellerbrand C, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 1998;160:410-18.
38. Hogaboam CM, Vallance BA, Kumar A, et al. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 1997;100:2766-76.
39. MacDonald TT. Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease. Gut 1998;42:460-1.
40. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
41. Westbrook CA, Chmura SJ, Arenas RB, et al. Human APC gene expression in rodent colonic epithelium in vivo using liposomal gene delivery. Hum Mol Genet 1994;3:2005-10.
42. Li M, Lonial H, Citarella R, et al. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Therapy 1996;3:221-9.
43. Hargest R, Williamson R. Prophylactic gene therapy for cancer. Gene Ther 1996;3:97-102.
44. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997;71:1842-9.
45. Schmid RM, Weidenbach H, Draenert GF, et al. Liposome mediated in vivo gene transfer into different tissues of the gastrointestinal tract. Z Gastroenterol 1994;32:665-70.
46. Alton EWFW, Middleton PG, Caplan NJ. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet 1993; 5:135-42.
47. Huard J, Lochmuller H, Acsadi G, et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995;2:107-15.
48. Wickham TJ, Lee GM, Titus JA, et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1996;71: 7663-9.